A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy.

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CORRECT
  • Sponsors Bayer
  • Most Recent Events

    • 02 Jun 2017 Results (n=505) of post hoc exploratory retrospective analysis assessing association between Hand-foot skin reaction (HFSR) and clinical outcomes, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 11 Oct 2016 Results of subgroup analysis of REG-treated patients in CORRECT trial with long and short PFS (n=505) presented at the 41st European Society for Medical Oncology Congress
    • 29 May 2015 Results of a post-hoc exploratory subgroup analysis of US patients were presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top